Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Sex differences in pharmacokinetics of cilostazol in rats.

Kamada N, Yamada K, Odomi M, Mukai T, Nishibayashi T, Ogawara K, Kimura T, Higaki K.

Xenobiotica. 2011 Oct;41(10):903-13. doi: 10.3109/00498254.2011.590242. Epub 2011 Jul 1.

PMID:
21718207
2.

Co-administration of tacrolimus suppresses pharmacokinetic modulation of multiple subcutaneously administered human interferon-alpha in Beagle dogs.

Yamazaki H, Miyake M, Kamada N, Nishibayashi T, Mukai T, Odomi M, Ishida T, Kiwada H.

Drug Metab Pharmacokinet. 2010;25(2):149-54.

3.

Effect of co-administration of tacrolimus on the pharmacokinetics of multiple subcutaneous administered interferon-alpha in rats.

Yamazaki H, Miyake M, Nishibayashi T, Mukai T, Odomi M, Ishida T, Kiwada H.

Pharm Res. 2009 Aug;26(8):1832-7. doi: 10.1007/s11095-009-9892-4. Epub 2009 May 5.

PMID:
19415469
4.

Novel oral absorption system containing polyamines and bile salts enhances drug transport via both transcellular and paracellular pathways across Caco-2 cell monolayers.

Mukaizawa F, Taniguchi K, Miyake M, Ogawara K, Odomi M, Higaki K, Kimura T.

Int J Pharm. 2009 Feb 9;367(1-2):103-8. doi: 10.1016/j.ijpharm.2008.09.027. Epub 2008 Sep 25.

PMID:
18929635
5.

Peptide derivation of poorly absorbable drug allows intestinal absorption via peptide transporter.

Kikuchi A, Tomoyasu T, Tanaka M, Kanamitsu K, Sasabe H, Maeda T, Odomi M, Tamai I.

J Pharm Sci. 2009 May;98(5):1775-87. doi: 10.1002/jps.21551.

PMID:
18781650
6.

In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol.

Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T.

J Control Release. 2008 Aug 25;130(1):29-37. doi: 10.1016/j.jconrel.2008.05.013. Epub 2008 May 19.

PMID:
18582979
7.

Importance of bile acids for novel oral absorption system containing polyamines to improve intestinal absorption.

Miyake M, Minami T, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T.

J Control Release. 2006 Oct 10;115(2):130-3. Epub 2006 Jul 21.

PMID:
16973235
8.

Optimization of suppository preparation containing sodium laurate and taurine that can safely improve rectal absorption of rebamipide.

Miyake M, Minami T, Oka Y, Kamada N, Yamazaki H, Kato Y, Mukai T, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T.

Biol Pharm Bull. 2006 Feb;29(2):330-5.

9.

Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids.

Miyake M, Minami T, Hirota M, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T.

J Control Release. 2006 Mar 10;111(1-2):27-34. Epub 2006 Jan 10.

PMID:
16410031
10.

Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.

Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T.

J Control Release. 2006 Mar 10;111(1-2):56-64. Epub 2006 Jan 10.

PMID:
16410029
11.

Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon-alpha in rats.

Yamada K, Odomi M, Okada N, Fujita T, Yamamoto A.

J Pharm Sci. 2005 Nov;94(11):2432-40.

PMID:
16200616
12.

Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage.

Yamada K, Kamada N, Odomi M, Okada N, Nabe T, Fujita T, Kohno S, Yamamoto A.

Int J Pharm. 2005 Apr 11;293(1-2):63-72.

PMID:
15778045
13.

Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine.

Miyake M, Kamada N, Oka Y, Mukai T, Minami T, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T.

J Control Release. 2004 Sep 14;99(1):63-71.

PMID:
15342181
14.
15.

Motor neuron involvement in a patient with long-term corticosteroid administration.

Mitsui T, Umaki Y, Nagasawa M, Akaike M, Ohtsuka S, Odomi M, Aki K, Matsumoto T.

Intern Med. 2003 Sep;42(9):862-6.

16.
17.

Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle.

Mitsui T, Azuma H, Nagasawa M, Iuchi T, Akaike M, Odomi M, Matsumoto T.

J Neurol. 2002 Aug;249(8):1004-9.

PMID:
12195445
18.

Mitochondrial damage in patients with long-term corticosteroid therapy: development of oculoskeletal symptoms similar to mitochondrial disease.

Mitsui T, Umaki Y, Nagasawa M, Akaike M, Aki K, Azuma H, Ozaki S, Odomi M, Matsumoto T.

Acta Neuropathol. 2002 Sep;104(3):260-6. Epub 2002 May 18.

PMID:
12172911
19.

Oxidative cleavage of the octyl side chain of 1-(3,4-dichlorobenzyl)-5-octylbiguanide (OPB-2045) in rat and dog liver preparations.

Umehara K, Kudo S, Hirao Y, Morita S, Uchida M, Odomi M, Miyamoto G.

Drug Metab Dispos. 2000 Aug;28(8):887-94.

PMID:
10901696
20.

In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms.

Abbas R, Chow CP, Browder NJ, Thacker D, Bramer SL, Fu CJ, Forbes W, Odomi M, Flockhart DA.

Hum Exp Toxicol. 2000 Mar;19(3):178-84.

PMID:
10889516
21.

Stereoselective S-oxidation and reduction of flosequinan in rat.

Kashiyama E, Yokoi T, Odomi M, Kamataki T.

Xenobiotica. 1999 Aug;29(8):815-26.

PMID:
10553722
22.
23.

Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.

Kudo S, Odomi M.

Eur J Clin Pharmacol. 1998 May;54(3):253-9.

PMID:
9681669
24.

Metabolism of 1-(3,4-dichlorobenzyl)-5-octylbiguanide in the dog.

Kudo S, Umehara K, Morita S, Uchida M, Miyamoto G, Odomi M.

Xenobiotica. 1998 May;28(5):507-14.

PMID:
9622852
25.

Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24.

Ozaki S, Kosaka M, Harada M, Nishitani H, Odomi M, Matsumoto T.

Cancer. 1998 Jun 1;82(11):2184-90.

PMID:
9610698
26.

Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes.

Umehara K, Kudo S, Odomi M.

Xenobiotica. 1997 Nov;27(11):1121-9.

PMID:
9413916
27.

Intracerebral penetration of carteolol hydrochloride in rats.

Kudo S, Umehara K, Abe Y, Furukawa M, Odomi M.

Psychopharmacology (Berl). 1997 Jun;131(4):388-93.

PMID:
9226741
28.

Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans.

Kashiyama E, Yokoi T, Odomi M, Funae Y, Inoue K, Kamataki T.

Drug Metab Dispos. 1997 Jun;25(6):716-24.

PMID:
9193873
29.

Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates.

Kitani M, Miyamoto G, Nagasawa M, Yamada T, Matsubara J, Uchida M, Odomi M.

Drug Metab Dispos. 1997 Jun;25(6):663-74.

PMID:
9193867
30.

Metabolism of carteolol by cDNA-expressed human cytochrome P450.

Kudo S, Uchida M, Odomi M.

Eur J Clin Pharmacol. 1997;52(6):479-85.

PMID:
9342584
31.

Simple and rapid quantitative assay of 13C-labelled urea in human serum using liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.

Tanigawa T, Mizo-oku Y, Moriguchi K, Suzuki T, Osumi T, Odomi M.

J Chromatogr B Biomed Appl. 1996 Aug 30;683(2):135-42.

PMID:
8891910
32.
33.

Ocular distribution of carteolol after single and repeated ocular instillation in pigmented rabbits.

Fujio N, Kusumoto N, Odomi M.

Acta Ophthalmol (Copenh). 1994 Dec;72(6):688-93.

PMID:
7747576
34.

Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan.

Kashiyama E, Yokoi T, Todaka T, Odomi M, Kamataki T.

Biochem Pharmacol. 1994 Jul 19;48(2):237-43.

PMID:
8053920
35.

Stereoselective S-oxidation of flosequinan sulfide by rat hepatic flavin-containing monooxygenase 1A1 expressed in yeast.

Kashiyama E, Yokoi T, Itoh K, Itoh S, Odomi M, Kamataki T.

Biochem Pharmacol. 1994 Apr 20;47(8):1357-63.

PMID:
8185644
36.

Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat.

Kashiyama E, Todaka T, Odomi M, Tanokura Y, Johnson DB, Yokoi T, Kamataki T, Shimizu T.

Xenobiotica. 1994 Apr;24(4):369-77.

PMID:
8059540
37.
38.
39.

Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans.

Ohnishi A, Ko Y, Fujihara H, Miyamoto G, Okada K, Odomi M.

J Clin Pharmacol. 1993 Mar;33(3):230-8.

PMID:
8385161
40.

[The determination of carteolol in human plasma and urine by high performance liquid chromatography].

Odomi M, Akiyama H, Matsuura K, Shimizu T.

Yakugaku Zasshi. 1985 May;105(5):459-63. Japanese. No abstract available.

PMID:
4032235
41.

High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma.

Akiyama H, Kudo S, Odomi M, Shimizu T.

J Chromatogr. 1985 Mar 22;338(2):456-9. No abstract available.

PMID:
3998031
43.

High-performance liquid chromatographic procedure for the determination of probucol in human plasma.

Kudo S, Akiyama H, Odomi M, Miyamoto G.

J Chromatogr. 1983 Oct 14;277:419-22. No abstract available.

PMID:
6643632

Supplemental Content

Support Center